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Background
Antiretroviral treatment leads to a reduction of virus-spe-
cific immune responses. We hypothesized that DNA vac-
cination during ART can increase effective virus-specific
immune responses and contribute to a 'functional cure',
while the virus remains suppressed.
Methods
SIVmac251-infected Indian rhesus macaques treated with
ART during the chronic phase of infection were vaccinated
intramuscularly using needle/syringe method (IM) or in
vivo  electroporation (EP) with optimized DNA vectors
producing the majority of SIVmac239 proteins. Immune
responses were monitored by flow cytometry. Animals
were released from ART and plasma viral loads were mon-
itored.
Results
Therapeutic immunization by the IM route effectively
induced recall responses able to reduce viremia by 0.9 log
upon ART release in ~half of the animals. Long-term virus
reduction (3–4 years follow-up) was observed in several
vaccinated animals, while none of the controls survived,
supporting the potency of the vaccine-induced recall
responses. DNA delivery via EP induced significantly
higher recall responses (up to 5% of SIV-specific T cells in
blood). These responses appeared rapidly, were broad (all
antigens) and robust in DNA vaccinated animals but not
in controls. Vaccination led to the induction of SIV-spe-
cific CD4+ and CD8+ T cells with EM and CM phenotype
& polyfunctional cells. Cellular immune responses were
found both in blood and in BAL, indicating induction of
recall responses also at mucosal sites. Repeated vaccina-
tion by 2nd round of therapeutic vaccination showed a
persistent virological benefit with additional >1 log10
reduction in viremia after release from ART.
Conclusion
DNA vaccination during ART is able to boost potent, effi-
cacious, and long-lasting antigen-specific recall immune
responses and has the advantage of repeated administra-
tion. Using the more efficient electroporation as DNA
delivery method greatly improves immunogenicity in
therapeutic vaccination. These data support the concept of
adding DNA therapeutic vaccination to the HAART regi-
men to boost the HIV-specific immune responses.
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